Saturday, June 3, 2023; 8:00 AM–11:00 AM CDT
Poster Session
Genitourinary Cancer—Kidney and Bladder

4530 Real-world outcomes among patients with advanced/metastatic renal cell carcinoma (mRCC) treated with cabozantinib or other tyrosine kinase inhibitors (TKIs) after checkpoint inhibitor (CPI) therapy. D Heng, G Doshi, P Dutailly, et al

Take-Home Message

• This retrospective study of 485 US patients with metastatic RCC compared the use of cabozantinib with that of other TKIs after immune checkpoint inhibitor (CPI) therapy. The primary endpoint was the real-world response rate during the first 6 months of treatment, which was 62.5% with cabozantinib and 46.0% with other TKIs.
• The study provides important real-world data on TKIs after immunotherapy. Cabozantinib was effective following CPI therapy in patients with metastatic RCC, regardless of prior TKI treatment.

4534 Phase 2 study of batiraxcept (AVB-S6-500, an AXL inhibitor) as monotherapy, in combination with cabozantinib (cabo), and in combination with cabo and nivolumab (nivo) in patients with advanced clear cell renal cell carcinoma (ccRCC). K Beckermann, M Campbell, N Haas, et al

Take-Home Message

• This trial studied batiraxcept in three cohorts of patients with ccRCC: batiraxcept monotherapy in relapsing patients without curative options; batiraxcept plus cabozantinib in patients who had at least one prior therapy; and batiraxcept plus cabozantinib and nivolumab in the first-line setting. The primary endpoint was objective response rate, and secondary endpoints included safety and overall and progression-free survival.
• Batiraxcept is a promising novel agent for RCC. Although monotherapy was well-tolerated, clinical activity was limited. Combinations demonstrated safety and tolerability. The batiraxcept/cabozantinib combination will be tested in a phase III trial.

4537 Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Updated results from a phase 2 trial. CH Lee, K Fitzgerald, M Voss, et al

4540 Health-related quality of life (HR-QOL) measures in renal cell carcinoma (RCC): Patient-reported relevance of items of the FKSI-19, EORTC QLQ-C30, and EQ-5D. C Bergerot, B Mercier, D Castro, et al

4554 89Zr-DFO-girentuximab for PET/CT imaging of clear cell renal cell carcinoma: Results from phase 3 ZIRCON study. B Shuch, A Pantuck, J-C Bernhard, et al

Saturday, June 3, 2023; 3:00 PM–4:30 PM CDT
Poster Discussion Session
Genitourinary Cancer—Kidney and Bladder

4518 First-line lenvatinib + pembrolizumab treatment across non-clear cell renal cell carcinomas: Results of the phase 2 KEYNOTE-B61 study. C-H Lee, H Gurney, V Atduev, et al

4520 Phase II study of cabozantinib (Cabo) with nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma with variant histologies (RCCvh). B McGregor, J Huang, W Xie, et al

Take-Home Message

• This phase II study reports on treatment intensification with combined cabozantinib/nivolumab/ipilimumab in patients with metastatic RCC with variant histologies. Of the 40 patients enrolled, 28 (74%) developed treatment-related grade ≥3 toxicity; 5 patients (13%) discontinued the study drugs due to toxicity. An objective response was achieved by 8 patients, with 5 patients maintaining response for more than 6 months. Median progression-free survival was 8.9 months.
• It will be interesting to see the results of triple therapy in non–clear cell RCC. The results thus far suggest activity in this population, in particular among those patients with a chromophobe histology.

Monday, June 5, 2023; 11:30 AM–2:30 PM CDT
Oral Abstract Session
Genitourinary Cancer—Kidney and Bladder

LBA4500 Efficacy and safety of atezolizumab plus cabozantinib vs cabozantinib alone after progression with prior immune checkpoint inhibitor (ICI) treatment in metastatic renal cell carcinoma (RCC): Primary PFS analysis from the phase 3, randomized, open-label CONTACT-03 study. T Choueiri, L Albiges, P Tomczak, et al

Take-Home Message

• Analysis of primary progression-free survival turns up potentially practice-changing negative data with IO-TKI in the second-line setting in patients with metastatic RCC.

4502 Final prespecified overall survival (OS) analysis of CLEAR: 4-year follow-up of lenvatinib plus pembrolizumab (L+P) vs sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC). R Motzer, C Porta, M Eto, et al

Take-Home Message

• The 4-year follow-up results of overall survival analysis of the CLEAR Trial are presented. Overall survival with the combination of lenvatinib and pembrolizumab (L+P) versus sunitinib in treatment-naïve patients with advanced RCC was maintained across MSKCC risk groups, as was progression-free survival. The ORR was higher with L+P than with sunitinib.
• The results of the analysis offer valuable long-term follow-up of a potent combination therapy.

Saturday, June 3, 2023; 3:00 PM–4:30 PM CDT
Poster Discussion Session
Genitourinary Cancer—Kidney and Bladder

4511 Fibroblast growth factor receptor 3 (FGFR3) alterations in PROOF 302: A phase III trial of infigratinib (BGJ398) as adjuvant therapy in patients (pts) with invasive urothelial carcinoma (UC). P Grivas, S Daneshmand, V Makarov, et al

4512 Impact of histology on the efficacy and safety of pembrolizumab (pembro) monotherapy for advanced urothelial carcinoma (UC) in the phase 3 KEYNOTE-045 and KEYNOTE-361 trials. P Giannatempo, J-PH Machiels, N Sassa, et al

4515 Estimated net benefit of avelumab (AVE) + best supportive care (BSC) vs BSC alone for patients (pts) with advanced urothelial carcinoma (aUC) using a quality-adjusted time without cancer symptoms or toxicity (Q-TWiST) analysis. T Powles, P Cislo, M Kirker, et al

Take-Home Message

• This post hoc study used a Q-TWiST analysis, an integrated measure that incorporates efficacy, safety, and patient-reported outcomes, to assess quality-of-life differences in the context of survival between treatment groups in the JAVELIN Bladder 100 trial.
• JAVELIN Bladder 100 compared avelumab plus best supportive care with best supportive care alone in patients with advanced urothelial carcinoma. The results of this analysis indicate that patients who received avelumab plus best supportive care experienced a consistently longer Q-TWiST than the patients who received only best supportive care. They progressed more slowly and lived longer.

4516 Long-term safety of avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC) in the JAVELIN Bladder 100 trial. J Bellmunt, JB Aragon-Ching, MÁ Climent, et al

Monday, June 5, 2023; 7:30 AM–8:00 AM CDT
Late-Breaking Abstract Session
Genitourinary Cancer—Kidney and Bladder

LBA4619 Phase 3 THOR study: Results of erdafitinib (erda) versus chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select fibroblast growth factor receptor alterations (FGFRalt). Y Loriot, N Matsubara, SH Park, et al

Monday June 5, 2023; 11:30 AM–2:30 PM CDT
Oral Abstract Session
Genitourinary Cancer—Kidney and Bladder

4503 Overall survival (OS) by response to first-line (1L) induction treatment with atezolizumab (atezo) + platinum/gemcitabine (plt/gem) vs placebo + plt/gem in patients (pts) with metastatic urothelial carcinoma (mUC): Updated data from the IMvigor130 OS final analysis. E Grande, As Bamias, MD Galsky, et al

4504 Erdafitinib (ERDA) vs ERDA plus cetrelimab (ERDA+CET) for patients (pts) with metastatic urothelial carcinoma (mUC) and fibroblast growth factor receptor alterations (FGFRa): Final results from the phase 2 Norse study. AO Siefker-Radtke, T Powles, V Moreno, et al

Take-Home Message

• Reported here are the final results of a phase II study of erdafitinib (ERDA) versus ERDA plus cetrelimab (ERDA+CET) in the first-line setting in cisplatin-ineligible patients with FGFR alterations and metastatic urothelial carcinoma. By data cutoff, 87 patients had been randomized (44 to ERDA+CET and 43 to ERDA) and treated. The overall response rate was 54.5% with ERDA+CET (6 complete responses) compared with 44.2% with ERDA (1 complete response). The 12-month overall survival rates were 68% and 56%, respectively. The occurrence of grade ≥3 treatment-related toxicity was 45.5% and 46.5% in the ERDA+CET and ERDA groups, respectively. Of the PD-L1–positive patients (4 in each arm), 75% (3/4) responded to ERDA+CET; none responded to ERDA monotherapy.
• The combination of ERDA and CET was well-tolerated, with clinically meaningful activity.

4505 Study EV-103 dose escalation/cohort A: Long-term outcome of enfortumab vedotin + pembrolizumab in first-line (1L) cisplatin-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC) with nearly 4 years of follow-up. S Gupta, JE Rosenberg, RR McKay, et al

LBA4507 Multicenter randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for muscle-invasive bladder cancer (MIBC): Overall survival (OS) data at 5 years in the GETUG/AFU V05 VESPER trial. C Pfister, G Gravis, A Flechon, et al

4508 SWOG S1011: A phase III surgical trial to evaluate the benefit of a standard versus an extended lymphadenectomy performed at time of radical cystectomy for muscle invasive urothelial cancer. SP Lerner, C Tangen, RS Svatek, et al

Take-Home Message

• Patients with muscle-invasive urothelial cancer undergoing radical cystectomy were randomized to a standard bilateral pelvic lymphadenectomy (including external and internal iliac and obturator lymph nodes) or to an additional extended lymphadenectomy (up to at least the aortic bifurcation including common iliac, presciatic, and pre-sacral nodes) to determine if the extended procedure conferred improved disease-free and overall survival outcomes compared with standard lymphadenectomy.
• Extended lymphadenectomy was associated with a greater degree of morbidity and higher rates of peri-operative mortality. No significant disease-free or overall survival benefit was gained with the extended procedure compared with the standard.

ASCO 2023, aanbevolen abstracten, blaaskanker, nierkanker, Dr. Eric Jonasch, Guru P. Sonpavde, MD

---

• ASCO 2022: aanbevolen abstracten gerelateerd aan blaaskanker en nierkanker door internationale oncologen.

---

• ASCO GU 2022: Abstracten gerelateeerd aan blaaskanker en urineleiderkanker gepresenteerd op het American Society of Clinical Oncology Genitourinary Cancers Symposium van 17 t/m 19 februari 2022

---

• ASCO 2020: aanbevolen abstracten bij blaaskanker, urinewegkanker en zaadbalkanker. Plus 1 studie bij peniskanker

---

• Regulier - blaaskanker: actuele ontwikkelingen en belangrijke studies binnen de reguliere oncologie: een overzicht